Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study Evaluating the Safety and Efficacy of WL276 CAR-T Cell Therapy in CD276 Positive Recurrent or Progressive Glioblastoma Patients

NCT06691308 is registered in ClinicalTrials.gov with Beijing Immunochina Medical Science & Technology Co., Ltd. as lead sponsor.

NCT NCT06691308
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06691308 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study Evaluating the Safety and Efficacy of WL276 CAR-T Cell Therapy in CD276 Positive Recurrent or Progressive Glioblastoma Patients
Lead sponsor
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
November 12, 2024
Completion date
May 31, 2027
Enrollment
6 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent or progressive glioblastoma